

Poly Medicure Limited

Regd. Office: 232 B, 3rd Floor, Okhla Industrial Estate,
Phase-III, New Delhi - 110 020 (INDIA)
T: +91-11- 33550700, 47317000
E: info@polymedicure.com W: polymedicure.com
CIN: L 40300DL1995PLC066923



Date: 25th May, 2026

Scrip Code: - 531768

**The Manager,
BSE Limited,**
Department of Corporate Services,
Phirozee Jeejeebhoy Towers,
Dalal Street, Mumbai- 400001.

Scrip Code:- POLYMED

The Manager
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1-Block-G
Bandra Kurla Complex, Bandra(E),
Mumbai-400051.

Sub: Submission of Revised Investor's Presentation

Dear Sir/Madam,

Pursuant to Regulation 30 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Revised Investor's Presentation with respect to Audited Financial Results (Standalone & Consolidated) for Fourth Quarter and Financial Year ended on March 31, 2026.

The same is also available on the website of company i.e. www.polymedicure.com .

Request you to take the same on records.

Thanking You,
Yours Sincerely

For Poly Medicure Limited

Avinash Chandra
Company Secretary
M. No. A32270





Plan1Health

PendraCare

citieffe
Essential moves in Trauma

Investor Presentation Q4 & FY26 Results

Poly Medicure Ltd.
25th May 2026

Disclaimer

This presentation has been prepared by Poly Medicure Limited (the "Company"), content of which was compiled from sources believed to be reliable for informational purposes only and are based on information regarding the Company and the economic, regulatory, market and other conditions as in effect on the date hereof. Subsequent developments may impact the information contained in this presentation, which neither the Company nor its advisors or representatives are under an obligation to update, revise or affirm. Contents in the Presentation do not constitute or form part of an offer or invitation for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities, nor shall it or any part of it form the basis of or be relied on in connection with any contract, commitment or investment decision in relation thereto in India, the United States or any other jurisdiction. Prospective and existing investors should make their own evaluation of the Company as the information provided here does not purport to be all inclusive or to contain all of the information a prospective or existing investor may desire. Interested parties shall conduct their own due diligence and investigation on the information, before relying and acting thereon. Company makes no representation or warranty as to the accuracy or completeness of this information and shall not have any liability for any representations (expressed or implied) regarding information contained in, or for any omissions from, this information or any other written or oral communications transmitted to the recipient in the course of its evaluation of the Company. This presentation may contain certain "forward looking statements", which are based on certain assumptions and expectations of future events. Actual future performance, outcomes and results may differ materially from those expressed in forward looking statements as a result of a number of risks, uncertainties and assumptions. Though such forward looking statements are based on reasonable assumptions, it can give no assurance that such expectations will be met. Neither the Company nor any of its advisors or representatives assumes any responsibility to update forward-looking statements or to adapt them to future events or developments.




A hand is shown interacting with a futuristic digital interface. The background is a dark blue space filled with a network of glowing white nodes connected by thin lines. A central circular dashboard with various gauges and data points is visible. The overall aesthetic is high-tech and digital.

Q4 and FY 26 Performance Summary and Key Updates

Standalone Performance Summary Q4 FY26 & 12M FY26

Figs in Rs. Crs unless specified

Margin,%



No of Patents
348

Cash & Cash Equivalents
796.8

RoCE²
17.4%

RoIC³
21.4%

- Gross Margin expansion by 130 bps in FY26 led by improving product mix and cost optimization initiatives
- Standalone EBITDA margin close to the higher end of the range of guidance (25% -27%) provided at the beginning of the FY

¹Excludes Other Income




²ROCE is calculated as (EBIT/ Average Capital employed); Average capital employed excludes remaining QIP funds & EBIT excludes related treasury income and one-time Labour Code impact,

³Refer Slide no.15 for calculation of Return on Invested Capital

Consolidated Performance Summary Q4 FY26 & 12M FY26

Figs in Rs. Crs unless specified

Acquisition Impact Margin, %



Q4 EBITDA was impacted by

- Consolidation of acquisitions done during FY 26
- One time provision impact of certain regulatory and employee costs in the subsidiary

No of Patents

399

Cash & Cash Equivalents

842.2



¹Operating EBITDA for FY 26 excludes the impact of acquisition related expenses of Rs 9.7 cr; excludes Other Income but includes share of income from associate company.

Q4 & FY26 financials include consolidation impact of PendraCare Group (23 Sep 2025 onwards) and Citieffe Group (07 Nov 2025 onwards)



FY 26: Improving Sequential Revenue Trajectory

Figs in Rs. Crs unless specified



H1 to H2 revenue growth of 21% in-line with the guidance provided

- Sustained efforts on customer engagement and pricing related changes reflected improving revenue performance despite challenging external environment
- Acquisitions of Citieffe and Pendracare Group creating roadmap for future growth in high-end technology segments

¹ Q2, Q3 and Q4 FY26 financials include consolidation impact of PendraCare Group (23 Sep 2025 onwards) and Citieffe Group (07 Nov 2025 onwards)

Key Updates

Key Business Updates

- As of 30th April'26, cumulative **stent deployments surpassed ~11K units; commercial sales of DEB initiated with positive clinician feedback**
- Successfully achieved sales of **450 dialysis machines** during FY26; total installed base of ~1000 machines
- **PACIFIER-** (DES - Clinical Registry of 2000 patients) **650+ Patients** enrolled. Patient enrollment to be completed in FY27
- **Acquired Medyneo** — Brazil based medical device co. that holds necessary registrations and other operating licenses to commercialize operations

Financial Highlights

- Consolidated Q4 FY26 revenue growth **21.3%**; Q4 FY26 **Domestic** revenue growth **25.0%** and **International** revenue grew by **19.4%**;
- Consolidated FY26 revenue growth **12.3%**; FY26 **Domestic** revenue growth **19.6%** and **International** revenue grew by **9.3%**
- **Highest ever standalone quarterly revenue in Q4 FY 26**
- **FY 26 Standalone Operating EBITDA at 26.8%, near the upper end of 25-27% guidance range;** FY26 Consolidated Operating EBITDA margin at **24.4%**,
- Adequate liquidity of **Rs 842.2 Crs** as at Mar 31, 2026; Capex spend of **Rs. 296 Crs** in **FY 26**

Product Launches & R&D

- **35 products launched in FY26**
- **R&D team strength of ~ 90** across India, Italy and Netherlands

ESG

- Achieved **~8% reduction in scope 2 emissions** compared to FY24-25 through increase utilization of solar and renewable energy PPA
- ~70% facilities are certified under ISO 14001:2015

Awards

- Recently received “**Custodian Award for Best CSR Initiative in Healthcare, Education and Social Welfare**” by Medgate Today
- Poly Medicure awarded “**Emerging Medical Devices Company of the Year in Cardiology**” at VOH BEAT 2025

The background of the slide is a dark blue, futuristic digital environment. A hand is shown in the center, with fingers reaching out towards a glowing network of white nodes connected by thin lines. To the right of the hand, there is a prominent circular graphic with concentric rings and a bright blue light source in the center, resembling a data visualization or a radar screen. The overall aesthetic is high-tech and data-driven.

Financial Performance Analysis

Standalone Financial Performance Summary

Figs in Rs. Cr. unless specified

Particulars	Q4 FY 26	Q4 FY 25	YoY Growth %	FY 26	FY 25	YoY Growth %
Revenue from Operations	443.0	421.0	5.2%	1,662.5	1,601.8	3.8%
Cost of Good Sold	147.9	143.9	2.7%	530.5	531.8	(0.2%)
Gross Profit	295.2	277.1	6.5%	1,132.0	1,070.0	5.8%
<i>Gross Profit %</i>	<i>66.6%</i>	<i>65.8%</i>	<i>81bps</i>	<i>68.1%</i>	<i>66.8%</i>	<i>128bps</i>
Employee Benefit Expenses	78.1	72.0	8.5%	313.1	280.1	11.8%
R&D Expenses	7.7	6.5	18.6%	29.8	24.0	24.2%
Other Expenses	88.3	82.4	7.1%	342.9	320.0	7.1%
Total Expenses	321.9	304.8	5.6%	1,216.4	1,155.9	5.2%
Operating EBITDA	121.1	116.2	4.2%	446.1	445.9	0.0%
<i>EBITDA %</i>	<i>27.3%</i>	<i>27.6%</i>	<i>(26bps)</i>	<i>26.8%</i>	<i>27.8%</i>	<i>(100bps)</i>
Other Income	15.1	23.9	(36.9%)	119.9	89.8	33.6%
Extra-ordinary expense*	-	-		6.8	0.0	
Depreciation	25.5	21.5	18.8%	97.9	81.4	20.3%
Finance Cost	3.9	2.2	79.6%	13.4	11.4	17.8%
PBT	106.8	116.5	(8.3%)	447.9	442.9	1.1%
Tax	26.2	29.8	(12.2%)	111.9	111.6	0.3%
PAT	80.6	86.7	(7.0%)	336.0	331.3	1.4%
<i>PAT %</i>	<i>17.6%</i>	<i>19.5%</i>	<i>(188bps)</i>	<i>18.9%</i>	<i>19.6%</i>	<i>(73bps)</i>
EPS - Basis	8.0	8.4	(5.4%)	33.2	33.4	(0.7%)
EPS – Diluted	8.0	8.4	(5.4%)	33.1	33.4	(0.8%)

*Basis Labour Codes notification (21 Nov 2025), a provision of Rs. 6.8Cr for past service gratuity & compensated absences has been recognized as an "Extraordinary Expense" for FY26
Re- classification has been done wherever necessary



Consolidated Financial Performance Summary

Figs in Rs. Cr. unless specified



Particulars	Q4 FY 26	Q4 FY 25	YoY Growth %	FY 26	FY 25	YoY Growth %
Revenue from Operations	534.5	440.8	21.3%	1,875.3	1,669.8	12.3%
Cost of Good Sold	178.2	148.1	20.3%	596.8	555.4	7.4%
Gross Profit	356.3	292.7	21.8%	1,278.4	1,114.4	14.7%
Gross Profit %	66.7%	66.4%	27bps	68.2%	66.7%	143bps
Employee Benefit Expenses	126.1	78.9	59.9%	402.3	301.5	33.4%
R&D Expenses	6.7	6.5	4.1%	29.9	24.0	24.4%
Other Expenses	113.1	87.7	28.9%	394.3	335.4	17.5%
Total Expenses	424.1	321.2	32.0%	1,423.2	1,216.4	17.0%
Share of Profit of an associate	1.7	2.3	(24.9%)	5.7	5.2	9.7%
Operating EBITDA	112.1	121.9	(8.0%)	457.7	458.6	(0.2%)
Operating EBITDA %	21.0%	27.6%	(667bps)	24.4%	27.5%	(305bps)
Other Income	17.8	24.3	(27.0%)	120.1	89.1	34.7%
Extraordinary Expense*	0.0	0.0		6.8	0.0	
Acquisition Related Expenses				9.7	0.0	
Depreciation	38.2	21.2	80.6%	115.5	83.2	38.9%
Finance Cost	6.4	2.2	195.7%	18.3	12.0	52.5%
PBT	85.2	122.8	(30.6%)	427.5	452.5	(5.5%)
Tax	20.2	31.0	(34.9%)	106.7	114.0	(6.3%)
PAT	65.0	91.8	(29.2%)	320.7	338.6	(5.3%)
PAT %	11.8%	19.7%	(796bps)	16.1%	19.2%	(317bps)
EPS - Basis	6.5	8.9	(26.7%)	31.8	34.1	(6.9%)
EPS - Diluted	6.5	8.9	(26.8%)	31.8	34.1	(6.9%)

*Basis Labour Codes notification (21 Nov 2025), a provision of Rs. 6.8Cr for past service gratuity & compensated absences has been recognized as an "Extraordinary Expense" for FY26
Re- classification has been done wherever necessary

Consolidated Sales Performance Analysis

Figs in Rs. Crs unless specified


Particulars	Q4 FY 26	Q4 FY 25	YoY Growth %	FY 26	FY 25	YoY Growth %
Domestic	168.7	135.0	25.0%	581.7	486.3	19.6%
International	361.9	303.0	19.4%	1,280.2	1,170.9	9.3%
Other Operating Revenue	3.8	2.8	35.3%	13.3	12.6	6.1%
Total Operating Revenue	534.5	440.8	21.3%	1,875.3	1,669.8	12.3%
Geographical Revenue Mix						
India	168.7	135.0	25.0%	581.7	486.3	19.6%
Europe	170.1	138.4	22.9%	597.0	557.4	7.1%
RoW	191.8	164.6	16.5%	683.2	613.5	11.4%
Other Operating Revenue	3.8	2.8	35.3%	13.3	12.6	6.1%
Total Operating Revenue	534.5	440.8	21.3%	1,875.3	1,669.8	12.3%



Segment Wise Sales Performance Analysis

Figs in Rs. Crs unless specified

Particulars	Q4 FY 26	Q4 FY 25	YoY Growth %	FY 26	FY 25	YoY Growth %
Infusion Therapy	256.1	251.4	1.9%	997.3	1,012.4	-1.5%
Renal	56.2	46.4	21.3%	187.6	150.7	24.5%
Others	222.1	143.1	55.2%	690.4	506.7	36.3%
Total Operating Revenue	534.5	440.8	21.3%	1,875.3	1,669.8	12.3%



Reclassification have been made where considered necessary

Balance Sheet Summary

Figs in Rs. Crs unless specified

Particulars	Standalone		Consolidated	
	As at Mar 31, 2026	As at March 31, 2025	As at Mar 31, 2026	As at March 31, 2025
Total Shareholders Funds	3,052.7	2,744.2	3,149.2	2,765.7
Equity Share Capital	50.7	50.7	50.7	50.7
Other Equity	3,002.0	2,693.6	3,055.5	2,715.0
Non Controlling Interest	0.0	0.0	43.1	0.0
Total Debt	248.4	169.9	341.6	177.6
Long Term Borrowings	2.5	0.0	52.1	0.0
Short Term Borrowing	245.9	169.9	289.5	177.6
Other Non Current Liabilities	77.7	56.3	148.6	58.5
Total Sources of Funds	3,378.8	2,970.3	3,639.4	3,001.9
Net Fixed Assets Incl. CWIP	1,290.5	1,119.7	1,345.7	1,127.8
Intangible Assets including under development	19.3	18.0	165.3	26.6
Goodwill	0.0	0.0	273.8	28.6
Other Non Current Assets	590.9	122.0	182.5	72.2
Cash & Cash Equivalents**	796.8	1,218.8	842.2	1,226.9
Current Assets	852.3	661.8	1,109.2	710.3
Less: Current Liabilities	(171.1)	(170.0)	(279.2)	(190.6)
Net Current Assets	681.2	491.8	830.0	519.7
Total Assets	3,378.8	2,970.3	3,639.4	3,001.9

Trade Working Capital- Standalone

Particulars	FY 26	FY 25
Debtors	442.2	340.1
Inventory	281.3	249.9
Creditors	84.7	76.7
Cash Conversion Days		
Debtor Days	98	78
Inventory Days	152	136
Creditor Days	35	31
Cash Conversion Cycle	215	183

**Includes Investments, Other Bank balances and Bank deposits (both current & non current)

Cash Flow Summary*

Figs in Rs. Crs unless specified

Particulars	Standalone	Consolidated
	FY26	FY26
Operating EBITDA	446.1	457.7
Extraordinary Item	(6.8)	(6.8)
Acquisition Related Expense		(9.7)
Other operating income and non cash expense	42.8	56.2
Tax Paid	(96.4)	(101.7)
Operating Cash Flow before WC Changes	385.7	395.7
Investment in Working Capital		
Changes in Inventory	(31.5)	(37.2)
Changes in Debtors	(90.7)	(99.3)
Changes in Payables	7.2	12.2
Other WC Changes	(23.8)	(21.9)
Operating Cash Flows	246.8	249.5
Investments		
Capex	(295.5)	(308.4)
Investment in Subsidiary	(439.9)	(386.0)
Advance against purchase of company through NCLT	(33.2)	(33.2)
Other Investing Cash Flows	18.9	20.4
Total Investing Cash Flows	(749.7)	(707.2)
Financing Cash Flows		
Change in Borrowings	78.5	74.6
ESOP Receipts	0.3	0.3
Interest Payments	(12.7)	(16.0)
Repayment of Lease Liabilities and Interest thereon	(2.7)	(3.3)
Dividend Paid (including unclaimed dividend transfer)	(35.4)	(35.4)
Total Financing Cash Flows	28.0	20.2
Net Cash Flow Generated	(474.7)	(437.5)
Unrealized gain on mutual fund	52.8	52.8
Opening Cash	1,218.8	1,226.9
Closing Cash (including unrealised Gains)	796.8	842.2

*drawn to reflect business performance summary, not necessarily in line with GAAP requirements

Standalone ROIC


Figs in Rs. Cr. unless specified

Particulars	As at Mar 31, 2026	As at Mar 31, 2025
Total Equity	3,052.7	2,744.2
Total Borrowings	248.4	169.9
Total Capital Employed	3,301.1	2,914.1
Less:		
- Cash & Cash equivalent	796.8	1,218.8
- Assets yet to be capitalized or unutilized*	146.3	89.5
- Investment in Subsidiaries/ associates	503.3	63.4
Invested Capital (A)	1,854.7	1,542.5
PBT	447.9	442.9
Interest Expense	12.9	10.2
Income on Liquid Investments (cash and cash equivalents above)	(67.3)	(58.9)
EBIT (B)	393.3	394.1
Return on Invested Capital (B/A)	21.4%	25.6%

- Given high capex and investment phase for Polymed, evaluating business performance on balance sheet level ROCE may not be relevant due to large undeployed capital
- Acquisitions made during the FY26 only have contributed partially to the financial performance of FY26.
- Given above points, computing ROIC (“Return on Invested Capital”) is a better metric to evaluate financial performance
- ***Despite low growth in FY 26, ROIC continues to remain in excess of 20%***

*includes CWIP, landbank currently unutilised

Shareholding Pattern as on 31st Mar 2026






Company Overview

Polymed Group : A Unique Medical Devices Platform

 **125+**
Countries

 **13**
Specialities

 **225+**
Medical Devices

 **15**
Manufacturing Plants
Across 5 countries

 **3300+**
Employee Base



 **570+**
Sales Associates


 **390+**
Patents Granted

 **1000+**
Distributors across
India & Globally

 **1.8 Billion+**
Devices Manufacturing
Capacity Per year


 **Largest Exporter**
Largest exporter of Consumable
Medical Devices for 10 years
in a row

Polymed Flywheel




Navigating Our Journey

Polymed's Path of Milestones and Triumphs



Moving Up the Technology Curve & Increasing TAM in High Growth Areas



Source: Industry Reports, Secondary Research

* Drug Eluting Stent

Driving Value through Strategic Acquisitions



Founded in **1995**, Located in **Amaro, Italy**

EN ISO 13485:2003 certified

Products Compliant with **EU MDR** and **CE marking requirements**

Many devices classified as **Class III Medical Devices** (long-term implantables)

End to end development capabilities

Post acquisition by Polymed, Plan -1 Health has grown by 20% CAGR annually and margins have improved by ~600 bps



Founded in **2011**, Located in **Leek Netherlands**

ISO 13485 and FDA certified

Product registration in more than 60 countries (CE / FDA / CFDA / ANVISA)

Trusted Supplier to medical devices industry leaders **for over a decade**

Only independent player of size and scale in Europe specializing in cardiology catheter business

Capacity of >1.5 million products per year; Current production is 700-800k units per year



Founded in **1962**, Located in **Bologna, Italy**

ISO 9001, ISO 13485 and FDA certified


MDR clearance across full portfolio; products registered in US, LATAM, and 25+ countries

Portfolio includes Internal Fixation, External Fixation systems, Instruments and a Unique navigation software for nailing systems

45+ patents. Dedicated **R&D team and 54+ KOL** across globe

Direct presence in Italy, US, Mexico with 85% of sales from countries with direct presence

Our Innovations Deliver Care to Key Clinical Specialties



Awards & Accolades



Himanshu Baid, MD, Poly Medicure, Healthcare Icon/Leader of the Year 2025 by ET Healthcare Awards



Himanshu Baid, MD, Poly Medicure Healthcare Entrepreneur of the Year 2025 by Financial Express



Medical Devices Provider of the Year 2025 by Financial Express



Innovative Health Technology Provider of the Year by ET Rajasthan Business Awards



Leading Brand in Medical Devices by Elets



Bhamashah Award by Govt. of Rajasthan, Education Dept.



Top Exporter of Plastic Medical Disposables from India for 10 Years by Plexconcil



Excellence in Medical Equipment Innovation by India Health Next Awards



Mr Himanshu Baid, MD, Poly Medicure, EY Entrepreneur of the Year Award 2024 - Lifesciences & Healthcare Category



Hurun India 2024 List of India's 500 Most Valuable Companies



Top 75 Industrial Innovative Company of the Year 2024 by CII



ET Best Healthcare Brands 2024




The Next 500 Companies 2023 by Fortune India



Levers of Value Creation

Polymed- One Company Many Engines of Growth





Global MedTech Scenario - APAC Growing the Fastest

\$ 680 bn
2025F Market Size

~20%
APAC as % of global medical devices market

~2%
India as % of global medical devices market




Global Medical Device Sector region-wise growth rate (CAGR, 25-30)

Source: BCG "Unlocking 'India for the World' in MedTech", Industry Reports, Secondary Research

India MedTech - Sunrise Sector Unveiling Enormous Growth Opportunities

India is the 4th Largest Market in Asia


India MedTech Market Size (in USD)



\$3: India's per capita MedTech spending, compared to global average of **\$47**

Key themes accelerating India's MedTech growth towards 2030 ambition

- Evolving disease patterns and trends in healthcare delivery
- Evolving Medtech Industry Ecosystem
- Substantial cost advantage in terms of MedTech manufacturing
- Demographics and socioeconomic factors
- Strong government support through regulatory and policy changes



Source: BCG "Unlocking 'India for the World' in MedTech", EY "India's MedTech industry: The renaissance of a sector" report, IBEF


Polymed's Manufacturing Footprint

15 Facilities across 5 countries

India Manufacturing Facilities



International Manufacturing Facilities



Plants with **multiple global certifications**

400+ Moulding Machines and 1800+ Molds & Dies

530+ Automatic Assembly Machines

130+ Robots are employed in our manufacturing processes



Company Driven by Innovation (R&D)



Core Development Capabilities

Product design, process design, mold design, automation and machine design



Team Strength

A dynamic workforce of **90+ professionals**, including **45+ skilled engineers across India, Italy and Netherlands**



Clinical Data driven strategy


2000+ patients enrolled in the DES clinical registry, supporting the global expansion of our cardiology portfolio



Patents


390+ Patents Granted
60 Applications Under Review

New Product Launches



100+ products in pipeline to be launched in next 3-4 years

Recently Launched Products



Touching Millions Of Lives Every Day Across 125+ Countries




1000+ Global distributors including India and 570+ sales associate



-  POLYMED HQ
-  MANUFACTURING UNITS
-  PLAN1HEALTH
-  NEW PLANTS
-  OUR PRESENCE
-  CITIEFFE
-  PENDRACARE GROUP
-  Countries with Direct Presence

Robust Financial Performance Delivering Strong TSR#

Amount in INR Cr.



Returns ratios are lower in FY26 partly due to partial period consolidation of acquisitions and high capex intensity

* Excludes the amount raised through QIP in August 2024, and treasury income generated from the QIP Funds, lab our code impact and acquisition cost
basis consolidated financial statements




Diversified Segment and Geographic Mix

Segmental Revenue Mix

Numbers in INR crore unless specified

Particulars	FY 23	FY 24	FY 25	FY26	CAGR (23-26)
Infusion Therapy	771	925	1,012	997	9%
Renal	76	94	151	187	35%
Others	269	356	507	691	37%
Total Operating Revenue	1,115	1,376	1,670	1,875	19%

PORTFOLIO MIX




Geographical Revenue Mix

Numbers in INR crore unless specified

Particulars	FY 23	FY 24	FY 25	FY26	CAGR (23-26)
India	351	418	486	582	18%
Europe	335	454	558	597	21%
RoW	430	504	626	696	17%
Total Operating Revenue	1,115	1,376	1,670	1,875	19%

GEOGRAPHIC MIX



Strong Promoters and Experienced Leadership Team

Promoters



Mr. Himanshu Baid
(Managing Director)

Co-founder of Poly Medicure, Mr. Baid has over 30 years of experience in the medical device industry and has been instrumental in the company's growth and innovation. He was honored with the EY Entrepreneur of the Year Award, 2024 in the Life Sciences and Healthcare sector.



Mr. Rishi Baid
(Joint Managing Director)

Co-founder of Poly Medicure, Mr. Baid oversees operations and strategic initiatives, contributing significantly to the company's expansion and product development with an experience of 28 years.



Mr. Vishal Baid
(Executive Director)

Mr. Vishal Baid is responsible for overall Marketing and in charge of Manufacturing activities in Jaipur with an experience of 25 Years.



Mr. Jugal Kishore Baid
(Non-Executive Director)

A founding member, Mr. Baid has played a pivotal role in establishing the company's foundation and continues to provide strategic guidance with an experience of 56 years.

Experienced Leadership Team



Mr. Alessandro Balboni
(Non-Executive Non-Independent Director)

Mr. Balboni brings international business experience, particularly in the European healthcare market, enhancing the company's global perspective with an experience of 23 years.



Mr. Pankaj Kumar Gupta
(Executive Director)

Mr. Pankaj Kumar Gupta is an accomplished and result-driven Operations Leader with over 35 years of experience.



Mr. Rahul Gautam
(President – Strategy & Corporate Development)

Mr. Rahul Gautam has 20+ years of experience in Corporate Strategy, M&A and Capital Markets. He has led M&A and fundraising deals exceeding US\$8 billion.



Mr. Naresh Vijayvergiya
(Chief Financial Officer)

Mr. Naresh Vijayvergiya is an accomplished finance executive with 22+ years of experience culminating in CFO and President-level roles, driving financial strategy in manufacturing and commodities sector.

B Also a board member of Poly Medicure Ltd



Mr. Pascal Govi
(CEO – Citieffe Group)

Mr. Pascal Govi is a global medtech leader with 30+ years of experience, CEO of Citieffe since 2019 driving international growth.



Mr. Sander Hartman
(CEO – Pendracare)

Mr. Sander Hartman is a seasoned medical device executive with 20+ years of global experience, currently serving as CEO of PendraCare International. Associated with Pendracare group since 2012.



Mr. Heyward Powe
(Vice President, Sales & Business Development)

A senior medical device executive with over 27 years of experience in Vascular Access, Oncology, Cardiology, and Surgery. Currently, Vice President of Sales for North America and parts of South America at Polymed Inc.

Robust Governance Framework

Non-Executive Board



Mr. Devendra Raj Mehta
(Chairman, Non-Executive Non-Independent Director)

A seasoned IAS officer and former Chairman of SEBI, Mr. Mehta brings extensive regulatory and governance experience to the board with an experience of 54 years.



Mr. Vishal Gupta
(Non-Executive Independent Director)

Mr. Vishal Gupta is the Managing Director of Ashiana Housing Ltd., known for pioneering senior living and middle-income housing in India with an experience of 25 years.



Mr. Vimal Bhandari
(Non-Executive Independent Director)

An experienced finance professional, Mr. Bhandari provides valuable insights into financial planning and risk management with an experience of 35 years across IL&FS, AEGON N.V & IndoStar Capital Finance Limited.



Ms. Sonal Mattoo
(Non-Executive Independent Director)

Ms. Mattoo specializes in human resources and organizational development, supporting the company's talent management strategies with an experience of 28 years.



Dr. Ambrish Mithal
(Non-Executive Independent Director)

A renowned endocrinologist, Dr. Mithal provides medical expertise, aligning the company's products with healthcare needs with an experience of 39 years.




Mr. Amit Khosla
(Non-Executive Independent Director)

With a strong background in law and corporate affairs, Mr. Khosla aids in ensuring compliance and ethical standards with an experience of 24 years.

A hand is shown reaching out towards a glowing blue digital interface. The interface features a network of nodes connected by lines, with a central circular graphic that resembles a radar or a data visualization. The background is dark blue with bokeh light effects.

Way Forward

Polymed strategy shaped by Macro trends in the MedTech Industry



International Strategy – US

Entity

Presence

Regulatory Approvals

Growth Strategy

Polymed

4 distributors

4 approved;
3-4 in pipeline

- Reinitiated conversations with customers post reduction of US tariffs
- Focus on Infusion Therapy and Critical Care segments
- Revenue ramp-up expected in FY 27

Citieffe

Direct Presence

10 approved; 8-10 in pipeline

- Making additional investments to deepen customer engagement
- Plan to expand presence in states with existing hospital approvals or established relationships
- Addition of plates to the portfolio; to double TAM

Pendracare

Guiding catheter approved; In talks with distributors and global OEM; sales expected to start in current year

- Engaging with existing Polymed distributors
- Launching new products including new GC with improved technology
- Pursuing CD/CM with OEMs using combined PML-Pendracare capabilities

P1H

NA

1 approved for OEM

- In talks with existing Polymed distributor
- Evaluating product submissions for FDA approvals



International Strategy – Europe

Entity	Polymed	Citieffe	Pendracare	P1H
Presence	75+ distributors	Direct presence in Italy + 12 Distributors	17 distributors + 2 OEM relationship	20+ distributors
# Regulatory Approvals	82 approved; 15 in pipeline	Whole Portfolio (20+); 10+ in pipeline	2 approved; 3 in pipeline	Whole Portfolio (4 categories); 1 in pipeline
Growth Strategy	<ul style="list-style-type: none"> • New product approvals in FY27 to expand product basket • Leveraging recent acquisitions to expand presence in tender markets • Deepening customer engagement specifically on clinical side • Evaluating certain markets to build direct presence 	<ul style="list-style-type: none"> • Build direct presence in other large and similar European markets • Focus on developing new distributors in northern Europe • Addition of plates to the portfolio; to double TAM 	<ul style="list-style-type: none"> • New GC (co-developing with PM) to create new opportunities • Expanding sales by leveraging existing Polymed network • Working on multiple CD/CM opportunities using combined PML-Pendracare capabilities 	<ul style="list-style-type: none"> • Increase tender presence in Italy and other in EU markets • Launching new devices in Italy

India Growth Strategy

Import Substitution

Substituting imports with high quality Made in India products

- Proven capabilities in Infusion Therapy & Vascular Access
- Replicating success across Renal, Cardiology and Critical Care

Focused Therapy Areas

Infusion · Renal · Cardiology · Critical Care

Clinical Led Engagement

Greater focus on Clinical led engagements with stakeholders

- **PACE Academy**– 400+ nurses trained from 52 hospitals engaged; 4-5 new academies to set up including within Hospitals
- **4000+ clinical engagements** through IV Talks (INS) and Ascent+
- **SARATHII** - 3,000+ AI-led training sessions / 265 individuals; FY27 expansion planned across international teams and domestic verticals
- Focusing on evidence generation on clinically driven products



4,000+
Clinical Engagements

Portfolio Expansion

Expansion of product portfolio to help boost sales

- 25-30 new products per year over the next 3–4 years
- Registration of Pendracare and Citieffe products underway in India
- Plans to further boost P1H product sales in India through deeper penetration

25-30
New Products / Year
3–4 Year Product Roadmap

Expanding Footprint

Expand our footprint across India

- 100+ sales associates to be hired across India in FY 27
- Expanding existing network of 650+ distributors across India

100+
New Sales Hires

650+
Distributors

Towards our Commitment to a **Sustainable World**

Approx. 70% facilities are certified under ISO 14001:2015

ENVIRONMENTAL MANAGEMENT SYSTEM

- Annual Health check-up of 304 employees
 - One on one consultation with certified nutritionist- 115 employees
- 4668 employee training attendances recorded

EMPLOYEE WELLBEING

9.9 MWp solar energy

- Commissioned from 9th Nov 25
- Generated approx. 3297 MWh unit
- Reduced Scope-2 emission approx. 2341 tCO₂

SIGNED PPA AGREEMENT

- LCA of Prefilled Syringe completed as per ISO 14040/44
- LCA report of PFS has been verified as per ISO 14071

Life Cycle Assessment & Critical review

Achieved approximately 8% reduction in Scope 2 emissions compared to FY 24-25 through increased utilization of onsite solar and renewable energy PPA, despite commissioning of a new plant

SCOPE 2 EMISSION

Achieved 1% decrease in energy consumption compared to FY 24-25 despite commissioning of a new plant

ENERGY CONSUMPTION

Achieved 2.39x growth in solar power generation compared to FY 24-25

SOLAR GENERATION

SUSTAINABLE DEVELOPMENT

Thank You

For any investor related queries reach us at:

Apoorv.Rastogi@polymedicure.com